期刊文献+

Clinicopathological Features of Nondiabetic Renal Diseases from Different Age Groups:An Observational Cross-sectional Study 被引量:6

原文传递
导出
摘要 Background:Diabetes mellitus (DM)has become the leading cause of chronic kidney disease (CKD).Nondiabetic renal diseases (NDRDs) have different clinicopathological features and prognosis from those of diabetic nephropathy.Our study sought to analyze the clinical and pathological features of NDRDs,in different age groups through a cross-sectional study. Methods:All patients with type 2 DM at our center who underwent renal biopsy between March 1997 and March 2017 were screened and divided into three groups by age:Group 1 (youth group),18-44 years old;Group 2 (middle-aged group),45-59 years old;and Group 3 (elderly group),≥60 years old.We analyzed the clinicopathological data and risk factors by univariate and multivariate logistic regression for NDRD of the patients to identify the features of NDRD in different age groups. Results:We included 982 patients in the final analysis.Patients with NDRD accounted for 64.4%of all patients.IgA nephropathy (IgAN) was the most common pathological pattern in young patients with NDRD,accounting for 26.3%.In the middle-aged group,the two most common pathological patterns were IgAN and membranous nephropathy.Membranous nephropathy was the most common pathological pattern in elderly patients with NDRD,accounting for 29.3%.Consistent with pathological features,glomerular hematuria is a risk factor for NDRD in Group 1 (odds ratio [OR],26.514;95%confidence interval [CI],2.503-280.910;P =0.006).On the other hand,rapidly increasing proteinuria or nephrotic syndrome is a risk factor for NDRD in Group 2 (OR,5.921;95% CI,2.061-17.013;P =0.001)and Group 3 (OR,90.409;95%CI,6.198-1318.826;P =0.001). Conclusions:This single-center study showed that the proportion and composition of NDRD differ among different age groups. Consistent with pathological features,some clinical indices such as hematuria and proteinuria showed different features among different age groups.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2018年第24期2953-2959,共7页 中华医学杂志(英文版)
基金 grants from the National Basic Research Program of China (No.2015CB553605) National Key R and D Program of China (Nos.2016YFC1305500,2016YFC1305503) Science and Technology Project of Beijing China (No.D171100002817002) Chinese People's Liberation Army General Hospital (Nos. 2016FCTSYS-1043,16KMM08) Natural Science Foundation of China (Nos.81700629,61471399) Wu Jie Ping Medical Foundation (No.320.6750.16191) National Science-Technology Support Plan Projects (No.2015BAI12B06).
  • 相关文献

参考文献2

二级参考文献38

  • 1Cooper ME, Gilbert RE, Jerums G. Diabetic vascular complications. Clin Exp Pharmacol Physiol 1997; 24: 770-775. 被引量:1
  • 2Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234. 被引量:1
  • 3Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta- analysis of 102 prospective studies. Lancet 2010; 375: 2215- 2222. 被引量:1
  • 4Wingard DL, Barrett-Connor EL, Scheidt-Nave C, McPhillips JB. Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. A population-based study. Diabetes Care 1993; 16: 1022-1025. 被引量:1
  • 5Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clip. Endocrinol Metab 2009; 94: 3171-3182. 被引量:1
  • 6de Boer R.A, van Veldhuisen D J, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012; 272: 55-64. 被引量:1
  • 7Falcone C, Lucibello S, Mazzucchelli I, Bozzini S, D'Angelo A, Schirinzi S, et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmaco12011; 24:905-913. 被引量:1
  • 8Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem 2012; 58: 267-273. 被引量:1
  • 9Rabinovich GA, Rubinstein N, Toscano MA. Role of galectins in inflammatory and immunomodulatory processes. Biochim Biophys Acta 2002; 1572: 274-284. 被引量:1
  • 10de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009; 11: 811-817. 被引量:1

共引文献27

同被引文献13

引证文献6

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部